Outset Medical, Inc. (NASDAQ:OM) Receives $12.67 Consensus Price Target from Brokerages

Shares of Outset Medical, Inc. (NASDAQ:OM) have earned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $12.6667.

Several research analysts have recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a research report on Monday. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $7.00 target price on shares of Outset Medical in a report on Wednesday, December 17th. Stifel Nicolaus set a $14.00 price target on shares of Outset Medical and gave the company a “buy” rating in a research report on Tuesday, November 11th. BTIG Research restated a “buy” rating and issued a $17.00 price target on shares of Outset Medical in a report on Tuesday, December 16th. Finally, Wall Street Zen upgraded shares of Outset Medical from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th.

Outset Medical Stock Performance

Shares of OM stock opened at $3.70 on Wednesday. The firm has a market cap of $67.16 million, a price-to-earnings ratio of -0.28 and a beta of 2.07. Outset Medical has a 52-week low of $3.10 and a 52-week high of $25.35. The company has a quick ratio of 5.77, a current ratio of 7.09 and a debt-to-equity ratio of 0.69. The company’s 50 day moving average is $6.13 and its 200 day moving average is $12.42.

Institutional Trading of Outset Medical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Alyeska Investment Group L.P. acquired a new stake in shares of Outset Medical in the 1st quarter worth $18,836,000. Woodline Partners LP acquired a new stake in Outset Medical in the first quarter worth about $14,663,000. Pura Vida Investments LLC boosted its holdings in Outset Medical by 8,482.4% in the second quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock worth $8,243,000 after acquiring an additional 424,120 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Outset Medical during the third quarter worth about $5,324,000. Finally, Geode Capital Management LLC increased its holdings in shares of Outset Medical by 955.9% during the second quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock valued at $7,984,000 after acquiring an additional 376,196 shares in the last quarter.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.